Cover Image
市場調查報告書

敗血性休克:開發中產品分析

Septic Shock - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213041
出版日期 內容資訊 英文 92 Pages
訂單完成後即時交付
價格
Back to Top
敗血性休克:開發中產品分析 Septic Shock - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 92 Pages
簡介

敗血性休克,是由激烈的感染疾病引起致命性低血壓時產生的重篤狀態。敗血性休克,老年人和幼兒最常見。任何種類的細菌,都有成為敗血性休克的原因的可能性。細菌和菌類放出的毒素,可能引起組織損傷,低血壓,內臟器官功能降低。症狀有斑狀變色的皮膚,混亂,體溫降低發冷,極度四肢無力感,頭暈等。

本報告提供敗血性休克的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

敗血性休克概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

敗血性休克:企業開發中的治療藥

敗血性休克:大學/機關研究中的治療藥

敗血性休克:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

敗血性休克:企業開發中的產品

敗血性休克:大學/機關研究中的產品

敗血性休克的治療藥的開發企業

  • Adrenomed AG
  • Ferring International Center S.A.
  • Huons Co., Ltd.
  • InflaRx GmbH
  • Leading BioSciences, Inc.
  • Lixte Biotechnology Holdings, Inc.
  • Noxxon Pharma AG
  • Orion Oyj
  • Peptinov SAS
  • Pharmazz, Inc.
  • Spider Biotech
  • 武田藥品工業
  • ViiV Healthcare Limited
  • XImmune AB

敗血性休克:治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

敗血性休克:最近的開發平台趨勢

敗血性休克:暫停中的計劃

敗血性休克:開發中止的產品

敗血性休克:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8496IDB

Summary

Global Markets Direct's, 'Septic Shock - Pipeline Review, H2 2016', provides an overview of the Septic Shock pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Septic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Septic Shock and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Septic Shock
  • The report reviews pipeline therapeutics for Septic Shock by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Septic Shock therapeutics and enlists all their major and minor projects
  • The report assesses Septic Shock therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Septic Shock

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Septic Shock
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Septic Shock pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Septic Shock Overview
  • Therapeutics Development
    • Pipeline Products for Septic Shock - Overview
    • Pipeline Products for Septic Shock - Comparative Analysis
  • Septic Shock - Therapeutics under Development by Companies
  • Septic Shock - Therapeutics under Investigation by Universities/Institutes
  • Septic Shock - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Septic Shock - Products under Development by Companies
  • Septic Shock - Products under Investigation by Universities/Institutes
  • Septic Shock - Companies Involved in Therapeutics Development
    • Adrenomed AG
    • Ferring International Center S.A.
    • Huons Co., Ltd.
    • InflaRx GmbH
    • Inotrem S.A.
    • Lixte Biotechnology Holdings, Inc.
    • Noxxon Pharma AG
    • Octapharma AG
    • Orion Oyj
    • Peptinov SAS
    • Pharmazz, Inc.
    • Spider Biotech
    • Takeda Pharmaceutical Company Limited
    • Therashock, LLC
    • ViiV Healthcare Limited
    • XImmune AB
  • Septic Shock - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 3K3A-APC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adrecizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Aspidasept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BC-1215 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-936559 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BTZO-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Sepsis and Septic Shock - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HBN-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HBN-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HBN-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HU-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IFX-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • L-257 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LB-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levosimendan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-6229 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Motrem - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXD-21 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PMZ-2010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pooled plasma (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Proteins to Inhibit Nuclear Factor Kappa B for Septic Shock - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-190 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-056 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • selepressin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit TNF-Alpha for Septic Shock - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-14 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-9 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Septic Shock - Dormant Projects
  • Septic Shock - Discontinued Products
  • Septic Shock - Product Development Milestones
    • Featured News & Press Releases
      • Sep 13, 2016: Inotrem Successfully Completes Its First Phase I Clinical Trial with Motrem, a TREM-1 Pathway Modulator for the Treatment of Septic Shock
      • Jun 07, 2016: InflaRx initiates phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients undergoing complex cardiac surgery
      • Jan 28, 2016: InflaRx announces positive phase IIa top-line results from the SCIENS trial investigating IFX-1, a first-in-class anti-complement C5a antibody
      • Oct 08, 2015: Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan
      • Jun 16, 2015: Tenax Therapeutics Highlights New Scientific Publication Regarding the Potential Mortality Benefits of Levosimendan in Septic Shock Patients
      • Jan 02, 2013: Adrenomed Develops New Drug To Reduce Mortality From Septic Shock
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Septic Shock, H2 2016
  • Number of Products under Development for Septic Shock - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Septic Shock - Pipeline by Adrenomed AG, H2 2016
  • Septic Shock - Pipeline by Ferring International Center S.A., H2 2016
  • Septic Shock - Pipeline by Huons Co., Ltd., H2 2016
  • Septic Shock - Pipeline by InflaRx GmbH, H2 2016
  • Septic Shock - Pipeline by Inotrem S.A., H2 2016
  • Septic Shock - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016
  • Septic Shock - Pipeline by Noxxon Pharma AG, H2 2016
  • Septic Shock - Pipeline by Octapharma AG, H2 2016
  • Septic Shock - Pipeline by Orion Oyj, H2 2016
  • Septic Shock - Pipeline by Peptinov SAS, H2 2016
  • Septic Shock - Pipeline by Pharmazz, Inc., H2 2016
  • Septic Shock - Pipeline by Spider Biotech, H2 2016
  • Septic Shock - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Septic Shock - Pipeline by Therashock, LLC, H2 2016
  • Septic Shock - Pipeline by ViiV Healthcare Limited, H2 2016
  • Septic Shock - Pipeline by XImmune AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Septic Shock - Dormant Projects, H2 2016
  • Septic Shock - Dormant Projects (Contd..1), H2 2016
  • Septic Shock - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Septic Shock, H2 2016
  • Number of Products under Development for Septic Shock - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top